Jefferies maintained a Buy rating on Silence Therapeutics plc (SLN) on March 05, 2026. The SLN analyst rating was reiterated in a note saying the stock “looks cheap at $175M+ EV,” according to StreetInsider. The firm’s call arrived with a reported 7.0% ($0.36) price change since the note, and market participants should weigh valuation, clinical risk, and liquidity when sizing positions.

SLN analyst rating: Jefferies maintains Buy

Jefferies reiterated Buy on March 05, 2026, highlighting valuation upside versus peers. The note framed Silence Therapeutics plc as inexpensive at an enterprise value cited above, without naming a formal price target.

Analyst rationale and valuation comment

Jefferies described Silence as cheap at $175M+ EV, focusing on pipeline potential and capital structure. The report did not publish a numeric price target but emphasized relative value versus small-cap peers and biotechnology comparables StreetInsider article.

Market reaction and key metrics

The note coincided with a 7.0% ($0.36) price change since the publication time listed and with a market cap of $259,786,714. Traders will watch liquidity and short interest for follow-through after a reiterated Buy from a major house.

Historical analyst coverage and context

Analyst coverage of Silence Therapeutics plc has been limited compared with larger biotech names, and Jefferies remains one of the more prominent active firms on SLN. That sparser coverage can produce larger intraday moves when a notable house issues commentary.

Implications for investors from the SLN analyst rating

A maintained Buy from Jefferies signals conviction but not a new upgrade. Investors should see this as confirmation of prior positive views rather than fresh upside guidance. Position sizing should reflect the company’s clinical-stage profile and funding runway.

Meyka grade and how we view the call

Meyka AI rates SLN with a grade of B. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Our platform provides AI-powered market analysis and an internal view; grades are not guarantees and are not financial advice. Visit the Meyka SLN page for live data and models Meyka SLN page.

Final Thoughts

Jefferies’ decision to maintain a Buy on Silence Therapeutics plc on March 05, 2026 keeps the spotlight on valuation rather than delivering a new price target. The SLN analyst rating reinforces that a reputable firm views the shares as inexpensive at the stated enterprise value, but investors should note Jefferies did not publish a formal numeric target. Liquidity, pipeline milestones, and funding needs remain primary drivers for SLN’s near-term performance.

For investors, the practical takeaway is to treat this as confirmation rather than a catalyst. Risk-tolerant investors who accept biotech volatility may increase exposure, while conservative holders should monitor clinical readouts and cash runway. Remember, Meyka AI rates SLN with a grade of B, a composite that considers benchmarking, sector trends, growth metrics, and analyst sentiment. These grades are informational and not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.